Clinical Trial

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Study acronym: ALBAN
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 11, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, randomized, multicentric study in patients with high-risk non-muscle invasive bladder cancer who had never received BCG for this disease. The primary objective is to evaluate the efficacy of atezolizumab as measured by Event-Free survival.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2019-01-08; most recent amendment 2024-12-05.
Status change: Recruiting → Active, Not Recruiting 2023-12-05
Status change: Not Yet Recruiting → Recruiting 2019-04-01
Trial Details
NCT Number NCT03799835
Lead Sponsor UNICANCER
Collaborators: Hoffmann-La Roche
Conditions Bladder Cancer
Enrollment 517 participants
Start Date 2019-01-17
Primary Completion 2025-06 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2024-12-11